Intellia Therapeutics (NASDAQ: NTLA) — Perfil da empresa, notícias e dados financeiros
Intellia Therapeutics develops CRISPR/Cas9 gene editing therapies focusing on genetic disorders and innovative cell therapies.
Intellia Therapeutics
Intellia Therapeutics (NASDAQ:NTLA) is a biotechnology firm engaged in developing groundbreaking therapies using CRISPR/Cas9 technology for gene editing. This innovative approach allows for precise editing of the genome, offering potential treatments for genetic disorders and diseases with unmet medical needs. The company's portfolio includes in vivo programs targeting conditions like Transthyretin amyloidosis (ATTR), a life-threatening disease, and several ex vivo projects focusing on engineering next-generation cell therapies for cancer and other diseases. Intellia's objective is to harness the power of CRISPR/Cas9 to bring curative therapies to patients worldwide, demonstrating a commitment to advancing medical science and improving human health.
Resumo
Operações
Produtos e/ou serviços de Intellia Therapeutics
- CRISPR/Cas9 technology for genome editing, aimed at treating genetic diseases by modifying disease-causing genes.
- In vivo therapy for Transthyretin (ATTR) amyloidosis, a progressive condition affecting the heart and nerves.
- Ex vivo cell therapies for cancer, using engineered human cells to target and destroy cancer cells.
- Research on Hemophilia B treatments, focusing on correcting the gene responsible for this blood clotting disorder.
- Development of therapies for Alpha-1 Antitrypsin Deficiency (AATD), a disease that affects the lungs and liver.
- Collaboration on developing CRISPR/Cas9-based therapies for sickle cell disease, aiming to correct the mutated gene causing the disease.
equipe executiva do Intellia Therapeutics
- John M. LeonardPresident, CEO & Director
- Edward J. Dulac IIIExecutive VP, CFO & Treasurer
- Birgit SchultesExecutive VP & Chief Scientific Officer
- James E. BastaExecutive VP, General Counsel & Corporate Secretary
- Rachel E. HaurwitzCo-Founder
- Jennifer A. DoudnaFounder & Member of Scientific Advisor Board
- Derrick J. RossiFounder & Member of Scientific Advisor Board
- Rodolphe BarrangouFounder & Member of Scientific Advisor Board
- Luciano MarraffiniFounder & Member of Scientific Advisor Board
- Erik J. SontheimerFounder & Member of Scientific Advisor Board
Últimas notícias sobre a Intellia Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Intellia Therapeutics, em USD.
- Cap. de mercado
- 1,9 bi
- Receita (TTM)
- 59,5 mi
- P/L
- —
- LPA (diluído, TTM)
- -3.4
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 67,7 mi | -441 mi | -412,7 mi | |
| 57,9 mi | -534,3 mi | -519 mi | |
| 36,3 mi | -515,3 mi | -481,2 mi | |
| 52,1 mi | -458,2 mi | -474,2 mi |